STADA Arzneimittel AG (ETR:SAZ) received a €50.00 ($56.18) target price from equities researchers at Independent Research GmbH in a note issued to investors on Tuesday. The brokerage currently has a “sell” rating on the stock.

SAZ has been the subject of several other reports. S&P Global set a €66.00 ($74.16) price objective on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research report on Monday, May 29th. Commerzbank Ag set a €66.00 ($74.16) price objective on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research report on Tuesday, June 20th. Warburg Research set a €66.00 ($74.16) price objective on STADA Arzneimittel AG and gave the stock a “sell” rating in a research report on Thursday, June 8th. Finally, Kepler Capital Markets set a €62.50 ($70.22) price objective on STADA Arzneimittel AG and gave the stock a “sell” rating in a research report on Thursday, June 22nd. Three investment analysts have rated the stock with a sell rating and two have issued a hold rating to the company. The stock currently has a consensus rating of “Sell” and a consensus price target of €62.10 ($69.78).

Shares of STADA Arzneimittel AG (ETR:SAZ) opened at 58.325 on Tuesday. The firm has a market cap of €3.63 billion and a price-to-earnings ratio of 34.430. The stock’s 50 day moving average price is €64.88 and its 200 day moving average price is €56.75. STADA Arzneimittel AG has a one year low of €40.50 and a one year high of €67.60.

WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/06/27/independent-research-gmbh-analysts-give-stada-arzneimittel-ag-saz-a-50-00-price-target.html.

STADA Arzneimittel AG Company Profile

Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products.

Analyst Recommendations for STADA Arzneimittel AG (ETR:SAZ)

Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with MarketBeat.com's FREE daily email newsletter.